Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond-Reference-Cited by-同舟云学术

Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond

Published:2015-08 Issue:16 Volume:11 Page:2263-2266
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Gadaleta-Caldarola Gennaro¹,Divella Rosa²,Mazzocca Antonio³⁴,Infusino Stefania⁵,Ferraro Emanuela⁶,Filippelli Gianfranco⁵,Daniele Antonella²,Sabbà Carlo³,Abbate Ines²,Brandi Mario¹

Affiliation:

1. Division of Oncology, “Mons. R Dimiccoli” Hospital, Viale Ippocrate, 15, 76121 Barletta (BT), Asl BAT, Italy

2. Clinical Pathology Laboratory, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”, Viale Orazio Flacco, 65, 70100 Bari, Italy

3. Interdisciplinary Department of Medicine, University of Bari School of Medicine, Piazza G. Cesare, 11, 70124 Bari, Italy

4. National Institute for Digestive Diseases, IRCCS “Saverio De Bellis”, Via Turi 27, 70013, Castellana Grotte, Bari, Italy

5. Division of Oncology, “S Francesco di Paola” Hospital, Via Promintesta, 1, 87027 Paola (CS), ASP, Italy

6. Department of Internal Medicine & Clinical Specialties, University of Rome “La Sapienza”, Policlinico Umberto I, Viale del Policlinico, 155, 00161 Roma, Italy

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon.15.161

Reference13 articles.

1. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

2. BAY 43-9006 Inhibition of Oncogenic RET Mutants

3. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

4. Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5

5. Sorafenib in Advanced Hepatocellular Carcinoma

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FAT10 mediates the sorafenib-resistance of hepatocellular carcinoma cells by stabilizing E3 ligase NEDD4 to enhance PTEN/AKT pathway-induced autophagy;American Journal of Cancer Research;2024

2. Analysis of prognostic germline polymorphisms in patients with advanced hepatocellular carcinoma;Translational Gastroenterology and Hepatology;2023-10

3. Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma;Biochimie;2022-11

4. Regorafenib for the Treatment of Sarcoma;Current Treatment Options in Oncology;2022-09-30

5. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia;Bioorganic & Medicinal Chemistry;2022-02